Live Breaking News & Updates on Theranostics Committee

Stay updated with breaking news from Theranostics committee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Telix Pharmaceuticals Limited: Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

Telix Pharmaceuticals Limited: Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Region Flamande , Al Qahirah , Baden Wüberg , United Kingdom , North Melbourne , Simone Kleinendorst , Macarena Rodr , Stefano Fanti , Laszlo Papp , Clement Bailly , Sanjiv Sam Gambhir Young , Neel Patel , Fuad Novruzov , Eduards Mamlins , Karolien Goffin , Kyahn Williamson , Colin Hayward , Yehia Omar , Nuclear Medicine Division , Nuclear Medicine Cl , European Association Of Nuclear Medicine , Misr Radiology Center , Health Canada , University Hospital Duesseldorf , European Union ,

Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

MELBOURNE, Australia, Sept. 6, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces presentations featuring the Company's theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 - 13 September 2023. Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be presented in on oral session on Sunday 10 September. In addition, the congress program features the following Telix initiatives: Sponsored symposium on personalised diagnostics in urological cancers: the promise of nuclear medicine; Phase III ProstACT GLOBAL study of TLX591 investigational prostate cancer therapy; Artificial intelligence (AI) Segmentation and primary characterisation of prostate cancer lesions using models trained on 68Ga-PSMA-11 image datasets; Nobody ....

North Melbourne , Al Qahirah , United Kingdom , United States , Region Flamande , Kyahn Williamson , Eduards Mamlins , Karolien Goffin , Yehia Omar , Fuad Novruzov , Clement Bailly , Macarena Rodriguez Fraile , Neel Patel , Colin Hayward , Stefano Fanti , Sanjiv Sam Gambhir Young , Simone Kleinendorst , Laszlo Papp , Misr Radiology Center , European Association Of Nuclear Medicine , Australian Securities Exchange , University Hospital Leuven , European Union , University Hospital Duesseldorf , Department Of Nuclear Medicine , Telix Pharmaceuticals ,

Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today. ....

Matthew Beck , Astellas Pharma , Oncology Lg Chem Life Sciences , Exchange Commission , Prnewswire Actinium Pharmaceuticals Inc , European Association Of Nuclear Medicine , Actinium Pharmaceuticals Inc , Actimaba National Cancer Institute , Oncology Theranostics Committee , Investor Relations Communications , European Association , Nuclear Medicine , Theranostics Track , Theranostics Committee , Poster Title , Poster Number , Therapy Clinical Study , National Cancer Institute , Life Sciences , Actinium Pharmaceuticals ,